O6-methylguanine-DNA methyltransferase modulates cisplatin-induced DNA double-strand breaks by targeting the homologous recombination pathway in nasopharyngeal carcinoma
Open Access
- 4 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Biomedical Science
- Vol. 28 (1), 1-21
- https://doi.org/10.1186/s12929-020-00699-y
Abstract
The homologous recombination (HR) pathway is involved in DNA damage response (DDR), which is crucial to cancer cell survival after treatment with DNA damage agents. O6-methylguanine DNA methyltransferase (MGMT) is associated with cisplatin (CDDP) resistance in cancer cells; however, the underlying mechanisms remain unclear. Here, we explored the interactions between MGMT and the HR pathway in CDDP-activated DDR and their clinical implications in nasopharyngeal carcinoma (NPC). Human NPC cells were assessed using loss-of-function approaches in vitro. The expression correlations between MGMT and major proteins of the HR pathway were analyzed through Western blotting, quantitative real-time PCR, and bioinformatic analysis by using a public database. The physical interactions between MGMT and HR proteins were studied using co-immunoprecipitation and immunofluorescence analyses. Cell comet tails and γ-H2AX expression levels were examined to evaluate double-strand break (DSB) formation. Established immunofluorescence and reporter analyses were conducted to measure HR activity. Xenograft and cell viability studies were used to assess the therapeutic potential of MGMT inhibition in combination with CDDP and poly(ADP-ribose) polymerase (PARP) inhibitor, respectively. Among major proteins of the HR pathway, MGMT suppression inhibited CDDP-induced RAD51 expression. Bioinformatic analyses showed a positive correlation between MGMT and RAD51 expression in patients with NPC. Moreover, MGMT physically interacted with BRCA1 and regulated CDDP-induced BRCA1 phosphorylation (ser 988). In functional assays, MGMT inhibition increased CDDP-induced DSB formation through attenuation of HR activity. NPC xenograft studies demonstrated that MGMT inhibition combined with CDDP treatment reduced tumor size and downregulated RAD51 expression and BRCA1 phosphorylation. Furthermore, MGMT suppression increased PARP inhibitor–induced cell death and DSB formation in NPC cells. MGMT is crucial in the activation of the HR pathway and regulates DDR in NPC cells treated with CDDP and PARP inhibitor. Thus, MGMT is a promising therapeutic target for cancer treatments involving HR-associated DDR.Keywords
Funding Information
- Chi Mei Medical Center, Liouying (CLFHR10821)
- Ministry of Science and Technology, Taiwan (MOST 104-2314-B-384-010 and MOST 104-2314-B-400-026)
- National Health Research Institutes (CA-106-PP-41)
- Health Promotion Administration, Ministry of Health and Welfare (MOHW109-TDU-B-212–134020, WanFang Hospital, Chi Mei Medical Center, and Hualien Tzu-Chi Hospital Joing Cancer Center Grant-Focus on Colon Cancer Research)
This publication has 53 references indexed in Scilit:
- Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase InhibitionPLOS ONE, 2012
- Inhibition of ERβ Induces Resistance to Cisplatin by Enhancing Rad51–Mediated DNA Repair in Human Medulloblastoma Cell LinesPLOS ONE, 2012
- IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinomaMolecular Cancer, 2011
- Survival rate in nasopharyngeal carcinoma improved by high caseload volume: a nationwide population-based study in TaiwanRadiation Oncology, 2011
- Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cellsMolecular Cancer, 2011
- Mechanisms of Cisplatin NephrotoxicityToxins, 2010
- The DNA-damage response in human biology and diseaseNature, 2009
- Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant gliomaNeuro-Oncology, 2009
- Phase II Trial of Gliadel plus O6-Benzylguanine in Adults with Recurrent Glioblastoma MultiformeClinical Cancer Research, 2009
- Degradation of BRCA2 in Alkyltransferase-Mediated DNA Repair and Its Clinical ImplicationsCancer Research, 2008